🇺🇸 FDA
Pipeline program

BHV-8000, DaTSCAN 74 MBq/ml solution for injection, DaTSCAN 74 MBq/ml solution for injection, BHV-8000, Placebo for BHV-8000

BHV8000-301

Phase 3 small_molecule active

Quick answer

BHV-8000, DaTSCAN 74 MBq/ml solution for injection, DaTSCAN 74 MBq/ml solution for injection, BHV-8000, Placebo for BHV-8000 for Early Parkinson’s Disease is a Phase 3 program (small_molecule) at Biohaven Bioscience Ireland Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Biohaven Bioscience Ireland Limited
Indication
Early Parkinson’s Disease
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials